3 Stocks Under $50 That Fall Short

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

These dynamics can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. That said, here are three stocks under $50 to avoid and some other investments you should consider instead.

Carter's (CRI)

Share Price: $32.14

Rumored to sell more than 10 products for every child born in the United States, Carter's (NYSE:CRI) is an American designer and marketer of children's apparel.

Why Do We Avoid CRI?

1. Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
2. Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 6.5% for the last two years
3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Carter's is trading at $32.14 per share, or 14.6x forward P/E. Check out our free in-depth research report to learn more about why CRI doesn’t pass our bar.

Moderna (MRNA)

Share Price: $25.04

Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.

Why Are We Out on MRNA?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 50.5% annually over the last two years
2. Free cash flow margin shrank by 215.1 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
3. Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders

At $25.04 per share, Moderna trades at 5.8x forward price-to-sales. Dive into our free research report to see why there are better opportunities than MRNA.

Enovis (ENOV)

Share Price: $29.28

With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE:ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.

Why Do We Steer Clear of ENOV?

1. Sales tumbled by 6.5% annually over the last five years, showing market trends are working against its favor during this cycle
2. Negative returns on capital show that some of its growth strategies have backfired, and its falling returns suggest its earlier profit pools are drying up
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

Enovis’s stock price of $29.28 implies a valuation ratio of 9.1x forward P/E. If you’re considering ENOV for your portfolio, see our FREE research report to learn more.

Stocks We Like More

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.